Jaguar Health wins FDA fee waivers for Mytesi, Canalevia for fiscal 2027
JAGX•FDA waives 2027 user fees for Mytesi and Canalevia-CA1
- FDA granted Jaguar Health a PDUFA fee waiver for Mytesi for fiscal 2027, lowering expected regulatory user-fee costs.
- FDA’s Center for Veterinary Medicine also waived the fiscal 2027 fee for Canalevia-CA1, its conditionally approved canine diarrhea drug.
